Tech Company Financing Transactions

Capsida Biotherapeutics Funding Round

Versant Ventures and Westlake Village BioPartners invested in a $50 million Series A funding round for Capsida Biotherapeutics. The round was announced on 4/30/2021.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1290 Rancho Conejo Blvd.
Newbury Park, CA 91320
USA

Phone

Undisclosed

Website

www.capsida.com

Email Address

Not Recorded

Overview

We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Robert Cuddihy

        

Browse more venture capital transactions:

Prev: 4/30/2021: Sera Prognostics venture capital transaction
Next: 4/30/2021: Wasabi Technologies venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary